SQ, TDOC, VRTX: Cathie Wood is optimistic about doubling stocks

When Cathie Wood buys stocks, investors will follow her to buy, which seems to be the latest trend in the investment world.

In the popular saying, following Cathie Wood, there is money to be made. Even some time ago due to the rise in U.S. Treasury yields, technology stocks plummeted, and ARK funds suffered a frantic sell-off. Wood is still as stable as a mountain, and he issued a statement saying that everything was as early as we expected and was better than we expected. Technology stocks are a good time to buy bottoms and increase positions. Today, I will analyze Cathie Wood's heavy holdings from the company's fundamentals and future market prospects. Can it double in the long run?

Square (ranked first in ARKK's innovative technology ETF)

The financial technology giant Square is a revolutionary stock in the financial industry, breaking the traditional payment industry. Square is known for its seller ecosystem, which provides small businesses with point-of-sale solutions and analytical tools. In return, Square collects merchant fees as revenue from the gross payment volume (Gross Payment Volume, GPV) of the network. Between 2012 and 2019, this GPV soared from US$6.5 billion to US$106.2 billion. Although GPV may decline in 2020 due to the epidemic, the compound annual growth rate from 2012 to 2019 is 49%, indicating that it will return to its previous level in 2021.

It is worth noting that the Square seller ecosystem has been very effective in attracting larger merchants in recent years. Merchants with an average annual GPV of at least US$125,000 in the third quarter of 2020 accounted for 61% of the total GPV. Because this is a merchant fee-driven business, so more large companies use the platform to make Square make more money. Cash App had more than 36 million active users in the fourth quarter, an increase of 50% over the same period last year. Square is also gradually increasing the features available on the Cash App, making it more and more popular for individuals to conduct a wide range of financial transactions.

Of course, Square's peer-to-peer payment platform Cash App provides the largest amount of business. As millennials promote more digital payment methods, the monthly active user base of Cash App has surged (7 million at the end of 2017 and 30 million by mid-2020). Cash App provides Square with a variety of income collection methods, including payment transfer fees, merchant fees, investment, and bitcoin exchange fees. Cash App should become the main driver of the company's gross profit in 2021.

Overall, Square is a value growth stock. The company's current market value is about 103 billion US dollars, which is equivalent to 196 times PE and 7.8 times PS.

Square achieved initial success by providing payment processing services for small and medium businesses. Over time, the company expanded its products and services to include point-of-sale software, e-commerce platforms, payroll services, business debit cards, etc. Starting this month, Square now also operates a federally chartered bank. This opened the door for Square to provide small business loans to its customers.

The current transition from cash to digital payment is still in its infancy. Square is expected to grow through its sellers and Cash App ecosystem, and in the process will bring substantial benefits to investors.

Teladoc Health (Leader in Telemedicine)

Due to the epidemic, the development of telemedicine has made real progress in 2020. Teladoc Health is one of the biggest winners. Its stock price soared by nearly 140%.

However, so far, TDOC is still in the early stages of telemedicine. According to data, after the epidemic is over, the annual telemedicine market in the United States will grow to about 250 billion US dollars. If the international market is added, this number will be even greater, and TDOC will be less than 30 billion US dollars. There is still enough space.

TDOC should be the biggest beneficiary among them. Although Amazon announced plans to launch Amazon Care telemedicine services to its American employees this summer. Amazon also intends to provide the service to other companies later in 2021 to participate in the competition in the telemedicine market. But Mu Ji disagrees, thinking that Amazon will not pose a threat to TDOC. Continue to increase TDOC.

Sister Mu believes that TDOC is the global leader in virtual care. So far, more than 40% of Fortune 500 companies use TDOC's services, and it provides more comprehensive products than its competitors. The most important thing is that the growth prospects of TDOC are very broad, and the development space of telemedicine is large enough. Coupled with TDOC's acquisition of Livongo Health, which operates a digital health platform that can help individuals manage chronic diseases, which creates a huge cross-selling opportunity.

Vertex Pharmaceuticals

ARK Genomic Revolution ETF ranked sixth

Vertex Pharmaceuticals (VRTX) is currently the strongest performer among all the top stocks of Wood's ETF. Large biotech companies do not have any competitors in their core markets. Vertex's four approved cystic fibrosis drugs are the only drugs that treat the underlying cause of genetic diseases.

Vertex also uses its expertise to target other rare genetic diseases. It expects to report the key results of a Phase 2 study evaluating VX-864 in the treatment of liver disease alpha-1 antitrypsin deficiency in the next few months. The company's product line also includes candidates for rare blood diseases β thalassemia and sickle cell disease and rare kidney disease focal segmental glomerulosclerosis.

And Vertex has the potential to change conventional treatment methods, and this treatment has just entered Phase 1/2 research. If the cell therapy VX-880 succeeds in clinical trials, it may be able to enable type 1 diabetes patients to live independently of insulin.

Vertex has a cash reserve of 6.6 billion U.S. dollars and plans to use it to recruit mid- and late-stage candidates to further strengthen its product line. In the next few years, this biotech stock will continue to be a big winner. In the long run, both financial technology and telemedicine are closely related to people’s lives. These are the general trends in which people’s living habits are being reshaped and the new trends in future technological development. These general trends may be in the next few decades. In the span, change the global social, economic, and political landscape. It is believed that investors will continue to benefit from these changes and generate high returns.

Comments

ASML stock forecast 2025: is it time to buy now?

Hello everyone, recently, because the market has a lot of fears about rising interest rates and shrinking the balance sheet, the Nasdaq as a whole has fallen a lot, and each support has basically been broken one after another. The general price has also broken, so there is no good signal to increase positions in the short term. It may be safer to hold cash first and wait until the decline begins to slow down a little or see a really cost-effective price before considering adding positions. However, the long-term bull market in the future will not end because of this year's interest rate hike, and cash will only become more and more worthless in the long run. In the short-term continuous decline of the stock market, we must put our minds in a positive state. At the same time, we must properly organize our thoughts and positions, prepare bullets, and use this time to do our homework for the stocks we are interested in. In this way, when a good price appears in the future, you will be...

VRTX stock forecast 2025: Vertex is undervalued

Let's look at some biotech companies with stable cash flow and currently undervalued value stocks as targets for diversified portfolios. The company I shared today, called Vertex Pharmaceuticals (VRTX), is dedicated to the development of rare diseases, especially Cystic Fibrosis (CF). I have always had high respect for the rare disease group of pharmaceutical companies in the disease category. In addition, in the future, gene and cell therapies are subverting the role of rare diseases in the pharmaceutical industry, making rare diseases no longer uncommon. It's tasteless, but a field full of the future. Vertex Pharmaceuticals Inc. was established in 1989 by Joshua Boger and Kevin Kinsella. is headquartered in Boston. At that time, several very good research and development companies were established in the United States, including the aforementioned Regeneron, Gilead, and today's Vertex. Vertex In the past, he devoted himself to the development of small molecule drugs, wh...

AMD stock forecast 2025: Q2 is expected to perform strongly

Before the US stock market on July 19, US technology stocks continued their decline last Friday, and AMD's stock price also continued to fall. AMD will announce the results of the second quarter of 2021 on July 27. The market expects this performance to be strong, so this round of decline may be a great opportunity to buy the stock. financial indicator Due to the strong market demand for CPU and graphics cards in 2021, AMD’s revenue is expected to exceed the maximum value of the financial guidance. AMD’s C&G business is expected to grow the most because higher-priced AMD Ryzen and high-end AMD Radeon sales continue to increase. In terms of gross profit margin, the market expects AMD's gross profit margin in Q2 2021 will increase by 47% year-on-year. If the average selling prices of CPUs and GPUs continue to rise in Q2 of 2021, and the ASPs of CPUs and GPUs will increase in Q1 of 2021, the gross profit margin may also increase by 48%. CPU market sh...

Intel, Twitter, and Snapchat stock forecast 2025: latest quarterly earnings reports

Three technology companies, Intel, Twitter, and Snapchat, released their latest quarterly earnings reports. Let's take a look at their performance and the key information revealed at the earnings conference. Intel(INTC) stock forecast 2025 Several important data on Intel's earnings report beat expectations. Among them, earnings per share were US$1.28, higher than the expected US$1.06, an increase of 12% over the same period last year; total revenue was US$18.5 billion, beating analysts’ expectations of US$17.8 billion. However, in Intel's guidance for the next quarter, the Non-GAAP gross profit margin given is only 55%, which is far lower than the market's expected 59.2%. The reason given by Intel is that it is worried that supply chain problems will limit profitability, and the expected chip manufacturing business will bring additional costs. For chip companies, the market is most concerned about gross profit margin. TSMC fell last week b...

FB stock forecast 2022: Facebook’s latest earnings report analysis

Today I will interpret its just-announced financial report for the second quarter of 2021. combined with the digital advertising industry's general development direction and competitive landscape. First, let’s summarize Facebook’s latest earnings report. I think Facebook’s second-quarter earnings report is very, very good. We can see how good it is from year-on-year and quarter-on-quarter. Revenue in the second quarter increased by 56% year-on-year, while it increased by 48% year-on-year in the first quarter. Operating profit in the second quarter increased by 107% year-on-year, while the first quarter increased by 93% year-on-year. Net profit increased by 101% in the second quarter, compared with a year-on-year growth of 94% in the first quarter. Earnings per share in the second quarter increased by 101% year-on-year, while the first quarter increased by 93% year-on-year. The operating margin in the second quarter was 43%, compared to 32% in the same period last year. The perform...

NIO and Tesla(TSLA) stock forecast 2025: released important news

In the past two days, two electric vehicle companies, NIO and Tesla have released important news. However, the market gave mixed reactions, one rose and the other fell. Let's take a look at what happened. To NIO stock forecast 2025 Let me talk about NIO first. NIO announced this morning that the company will issue additional shares totaling US$2 billion. The price of the additional issuance will be based on the current market price, and the timing of the issuance will be determined according to the company’s needs. It may be a one-time sale or a share. Wholesale sale. After calculation, this will cause about a 3% equity dilution for existing shareholders. However, the market seems to have given more interpretation. Today, NIO's share price has fallen by 6.3%, which is more than twice the theoretical dilution. To From the prospectus, the company only stated broadly that the funds raised will be used to strengthen its bala...

C3.ai stock forecast 2025: Is it time to buy now?

Few emerging technologies are as exciting as artificial intelligence. We have witnessed its ability to be applied in new ways, from quickly analyzing large amounts of data to improve the efficiency of hardware and software. C3.ai(AI) is one of the only companies in the world that develop artificial intelligence into independent services. In short, artificial intelligence is its entire business. Investors avoided such stocks this year because large technology companies began to engage in artificial intelligence projects, raising concerns about increased competitive threats. However, C3.ai continued to increase revenue, narrowed its losses, and added 82% of its customers in the fourth quarter of fiscal 2021. Therefore, the stock price has fallen about 60% so far this year, which may be a huge opportunity for those who want to get involved in this field. A unique business case Imagine that if a company needs to develop its own artificial intelligence, sim...

Can Apple（AAPL） icar end the dominance of Tesla（TSLA）?

Beginning in 2014, Apple started a plan for electric vehicles developed by "Project Titan". In the Apple electric car project, in the past few years, internal conflicts, leadership issues, and other issues have affected the entire project. The rumors in 2016 even hinted that Apple had shelved plans for the car, but Apple has overcome the development difficulties and still plans to develop consumers Car, The Apple car project has changed the leadership many times, and hundreds of employees have been laid off during the development process. In the past few years, there have been rumors that Apple has shifted its focus to autonomous driving software instead of just a car. In June 2017, Apple CEO Tim Cook publicly talked about Apple’s work on autonomous driving software, which rarely confirmed Apple’s development work, because Apple usually does not share the details it is studying, but when it comes to cars When it comes to software, due to legal restrictions, it has to apply fo...

NFLX stock forecast 2025: plummeted 22% after the earnings report.

Time to talk about Netflix, which plummeted 22% after the earnings report. First of all, Netflix's financial report this time does have its thunderous place, but part of the reason for the 22% drop in one breath is because the market sentiment has been very bad recently. At this time, the financial report thunderous will be punished more than usual. It is a wake-up call for companies that are about to report financial reports in the future, so we try to hold the stocks in the hands of companies with relatively stable historical financial reports and try to balance our positions as much as possible, to reduce the risk of financial report storms. After all, this quarter In a more dangerous period, back to the point. Let's take a look at Netflix's financial report this time. In the fourth quarter of 2021, Netflix's EPS was $1.33, exceeding analysts' estimates of $0.82, and revenue was just in line with expectations, with $7.71 billion, an increase of 16% year-on-year...

PLTR stock forecast 2025： Cathie Woods increased Palantir stock position

Software company Palantir (PLTR) released the latest quarterly earnings report, which performed very well. After the financial report, Palantir's stock price soared to 14.64% at the highest point. At the same time, the keen Cathie Woods also bought $140 million in Palantir stock. I won't talk about Palantir's specific business. If you don't know much about it, you can go back to my previous article. Let's talk back to the financial report. Benefiting from the benefits of the US government’s contract renewal, Palantir’s earnings per share and total revenue both beat expectations for this quarter’s earnings report. Among them, earnings per share were $0.04, beating the expected $0.01; total revenue was 376 million, an increase of 49% from the same period last year, slightly higher than the expected $361 million. Although the extent of beating expectations is not very large, the biggest highlight of the financial report is to broaden the business. ...

FinanceLinkway

Search This Blog